Johnson & Johnson EDURANT/rilpivirine — Percent Change (as a percent) increased by 1662.5% to 14.1% in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 31.8%, from 10.7% to 14.1%. This is a positive signal — higher values indicate stronger performance for this metric.
Positive growth rates suggest strong market penetration or successful lifecycle management, whereas negative rates indicate potential market saturation or loss of market share to newer therapies.
This metric measures the period-over-period percentage growth or decline in net sales for the EDURANT (rilpivirine) prod...
Comparable to year-over-year or quarter-over-quarter revenue growth percentages reported for specific blockbuster drugs or key therapeutic assets by peer pharmaceutical firms.
jnj_segment_edurant_rilpivirine_percent_change_as_a_percent| Q2 '21 | Q3 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | 2.3% | 9.6% | 1.8% | -14.3% | -5.2% | 7.6% | 12.8% | 18.6% | 21% | 15.7% | 11% | 11.5% | 10.7% | 21.6% | 16.4% | 0.8% | 14.1% |
| QoQ Change | — | +317.4% | -81.3% | -894.4% | +63.6% | +246.2% | +68.4% | +45.3% | +12.9% | -25.2% | -29.9% | +4.5% | -7.0% | +101.9% | -24.1% | -95.1% | >999% |
| YoY Change | — | — | — | -721.7% | -154.2% | — | +611.1% | +230.1% | +503.8% | +22.7% | -40.9% | -45.2% | -31.8% | +96.4% | +42.6% | — | +31.8% |